ABT
Abbott Laboratories
$87.83
▼ 0.7%Updated Today 7:15 PM ET
▼ Down 33.2% over the last 12 months
Market Cap
$153.99B
P/E
24.48x
Forward P/E (est.)
34.98x
ROE
12.2%
Revenue Growth
6.6%
EPS Growth
-53.6%
Profit Margin
13.9%
FCF Yield
5.3%
Debt / Equity
0.25x
ROIC
10.0%
Interest Coverage
12.64x
Current Ratio
1.39x
Dividend Yield
2.8%
Implied Growth (rev. DCF)
4.0%
Rating Score
53/100
Technical analysis reads price and volume to judge momentum and timing. It complements the fundamentals above — it does not replace them. Here is what ABT's chart says today, with each tool explained.
Trend — moving averages. A moving average is the average closing price over a window, which smooths out daily noise. ABT trades near $87.83, below its 50-day average ($90.13) and 200-day average ($113.64). Price below both averages is a downtrend — momentum is against buyers for now.
Momentum — RSI. The Relative Strength Index runs 0–100 and measures how strong recent gains are versus losses. Above 70 is "overbought", below 30 "oversold". At 58 it is in neutral territory — neither stretched nor washed out.
MACD. MACD compares two moving averages to flag shifts in momentum. Its histogram is currently positive — short-term momentum is improving.
Volatility — ATR. Average True Range is the typical daily move. ABT's is $2.24 (~2.6% of price), so swings of about that size each day are normal — handy for setting a stop that isn't too tight.
Support & resistance. Over the last month ABT found buyers near $84.96 (support) and sellers near $92.73 (resistance); its 52-week range is $81.97–$139.06. A decisive break beyond either edge often marks the next move.
Volume. The latest session traded 3.1× the 20-day average — heavier than usual, which adds conviction to the move. Rising volume on up-days suggests real buying; on down-days, real selling.
Educational information to help you read a chart — not a recommendation or a forecast. It updates daily as the price and indicators change.
Abbott Laboratories (ABT) is a large-cap company in the Health Care Equipment industry, part of the Health Care sector of the S&P 500, with a market value around $153.99B.
In its latest reported year it generated about $44.33B in revenue and $6.52B in net profit.
Our model rates ABT Neutral (53/100) on growth, profitability, financial health, and valuation. The summary below is built from its filed financials and current ratios and refreshes automatically.
4Y CAGR
0.7%
Revenue moved from $43.08B in 2021 to $44.33B in 2025, a 0.7% compound annual growth rate. The most recent year grew a steady 6.6% year over year. Slower, mature growth is common for established businesses.
Gross Margin
56.5%
Operating Margin
18.2%
Net Margin
14.7%
ROE
12.2%
Abbott Laboratories keeps about 13.9% of each sales dollar as net profit, with a 56.5% gross margin and 18.2% operating margin. Return on equity is 12.2% and return on invested capital about 10.0%. Margins are moderate — typical of a competitive but profitable business.
Total Debt
$12.93B
Net Debt
$6.13B
Net Debt / EBITDA
0.76x
Debt / Equity
0.25x
Leverage: debt-to-equity is 0.2x, and operating profit covers interest about 12.6x, with a current ratio of 1.4x. That is a conservative balance sheet — a cushion in downturns. It carries roughly $12.93B of total debt against $6.80B of cash.
Operating CF
$9.57B
Free Cash Flow
$7.39B
FCF Margin
16.7%
In the latest year Abbott Laboratories produced about $9.57B of operating cash flow and $7.39B of free cash flow after capital spending. That is a free-cash-flow yield of about 5.3% on today's price. Strong cash generation funds dividends, buybacks, and reinvestment.
P/E
24.48x
P/S
3.55x
P/B
4.08x
EV / EBITDA
—
ABT trades at 24.5x trailing earnings (about 35.0x on estimated forward earnings), 3.6x sales, and 4.1x book value. Reverse-engineering today's price implies the market expects roughly 4.0% long-term free-cash-flow growth. That is a fairly typical valuation for a profitable company.
Where this stock sits versus what most companies trade at.
Typical ranges are general references (e.g., many stocks trade at ~18–26x earnings), not hard rules. Context only — not investment advice.
How ABT stacks up against its Health Care peers — valuation, profitability, and growth versus the sector median.
In the Health Care sector (59 S&P 500 companies), ABT ranks #27 of 59 by our overall rating. It trades at roughly in line versus the sector on earnings (24.5x P/E vs. 25.4x median) with a lower return on equity (12.2% vs. 14.9%) and slower revenue growth (6.6% vs. 7.9%).
P/E vs sector
24.5x
median 25.4x
ROE vs sector
12.2%
median 14.9%
Growth vs sector
6.6%
median 7.9%
Sector rank
#27
of 59 by rating
Valuation vs. quality map
The sweet spot is upper-left: more profitable (higher ROE) for a lower P/E. Dashed lines mark the sector median.
Peers are the closest Health Care companies by sub-industry and size. Sector median is across all 59 S&P 500 names in the sector. Educational, not a recommendation.
Project revenue → earnings → price. Edit the assumptions to build your own case.
2030 price target (Base Case)
$74.96 – $128.50
vs. $87.83 today · expected CAGR -3% – 8%
| Metric | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| Revenue | $47.43B | $50.75B | $54.30B | $58.10B | $62.17B |
| Net income | $7.11B | $7.61B | $8.15B | $8.72B | $9.33B |
| EPS | $4.08 | $4.37 | $4.68 | $5.00 | $5.35 |
| Share price (low) | $57.18 | $61.19 | $65.47 | $70.05 | $74.96 |
| Share price (high) | $98.03 | $104.89 | $112.24 | $120.09 | $128.50 |
| CAGR (low–high) | -35% / 12% | -17% / 9% | -9% / 9% | -5% / 8% | -3% / 8% |
Educational model on sample fundamentals — not a forecast or investment advice. Outputs are only as good as your assumptions.
The case for ABT:
- Healthy free-cash-flow yield (~5.3%) funds buybacks and dividends.
- A conservative balance sheet (debt/equity 0.2x) lowers risk.
- Pays a 2.8% dividend on top of any price gains.
The case against ABT:
- Like any single stock, it is exposed to competition, the economic cycle, and shifts in its end markets.
Market risk — sector rotation, the economic cycle, and broad sentiment move the stock regardless of fundamentals.
On balance, the picture is mixed: Abbott Laboratories is a large-cap health care business growing at a mature pace, with solid profitability, and a sound balance sheet. It trades at 24.5x earnings, which our model scores Neutral (53/100). Weigh this against your own goals and time horizon — this is educational information, not a recommendation.
Data notice. Fundamentals and financial statements are sourced from company filings (SEC EDGAR) and market-data providers; prices and market caps refresh on trading days and may be delayed. Ratings, projections, technical signals, and written summaries are model- or rule-generated for education and may simplify or lag the latest filings.
Not advice. Nothing on this page is investment advice or a recommendation to buy, hold, or sell any security. Do your own research and consult a licensed financial professional before investing.